Muccini et al. [22] studied the efficacy of Fostemsavir in one phase of the third trial involving 372 participants living with HIV-1 infection, failing the existing ARV treatment with multiple drug-resistant HIV infections; they found the drug effective in increasing CD4+ T-cells and decreasing HIV RNA. This evidence concerns the gene CD4 and HIV infectious disease.